重复粪菌移植治疗1型糖尿病合并胃肠病变的长期疗效与安全性
本研究对20例随机对照试验中的17例1型糖尿病合并严重糖尿病胃肠病变患者进行开放标签延长期治疗,按需重复粪菌移植(FMT),中位随访33.2个月。结果显示FMT可一致缓解症状,GSRS-IBS评分从基线60降至末次治疗35,且安全可耐受,多数不良事件轻微自限。
要点
- 重复按需FMT可长期缓解1型糖尿病合并严重胃肠病变的胃肠道症状。
- 末次FMT后GSRS-IBS评分较基线平均下降25分(95%CI -33, -18)。
- 重复FMT总体耐受良好,严重不良事件仅1例可能与FMT相关。
核心结论
- 重复按需粪菌移植对1型糖尿病合并严重糖尿病胃肠病变患者的长期治疗有效且安全。
研究设计与样本
- FMT以口服胶囊为主,无法吞咽胶囊者采用结肠镜给药;每2-3个月电话评估GSRS-IBS。
主要发现
- 共接受95次FMT,人均中位5次,治疗间中位间隔5.3个月。
- 末次FMT时GSRS-IBS评分从基线60(95%CI 54, 66)降至35(95%CI 29, 40),平均差-25(95%CI -18, -33)。
- 治疗后2周频繁排便(>7次/天)比例从19%(95%CI 10%, 28%)降至3%(95%CI 0%, 7%)。
- 正常粪便类型(Bristol量表3-5分)比例从28%(95%CI 18%, 39%)升至76%(95%CI 66%, 86%)。
临床怎么用
- 对1型糖尿病合并严重胃肠病变且症状反复者,可考虑按需重复FMT作为维持治疗。
- FMT优先采用口服胶囊,不能吞咽者可用结肠镜途径。
- 治疗期间每2-3个月用GSRS-IBS评估症状,并监测不良事件。
局限性
- 开放标签、无对照,样本量小(17例),结果需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Faecal microbiota transplantation (FMT) may alleviate gastrointestinal symptoms in individuals with diabetic gastroenteropathy, as demonstrated in a recent placebo-controlled trial. In most participants, symptom relief was transient, raising the need for repeated treatments. This study assessed the long-term efficacy, safety and feasibility of repeated, on-demand FMT as a maintenance treatment in this patient population. METHODS: All 20 participants from the randomised clinical trial were offered extended open-label treatment with FMT. Symptom assessments were conducted by telephone every 2-3 months using the Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-IBS). Secondary measures included bowel movement frequency, stool consistency assessed using the Bristol Stool Scale, perceived treatment benefit on a seven-point Likert scale, and adverse events (AEs). FMT was primarily given as oral capsules, and colonoscopy was used for participants who could not swallow capsules. RESULTS: Of the original 20 participants, 17 were included in the present study and followed from September 2021 to December 2024, with a median Duration of follow-up of 33.2 months (range 14.7-39.1 months). Participants received a total of 95 FMT treatments, with a median of five per participant and a median interval of 5.3 months between treatments. FMT induced consistent symptom relief, with reduced GSRS-IBS scores across multiple treatments. At the last FMT treatment provided, the mean GSRS-IBS score had decreased from 60 (95% CI 54, 66) at baseline to 35 (95% CI 29, 40), with a mean difference of -25 (95% CI -18, -33). The occurrence of frequent bowel movements 2 weeks after treatment (> 7 per day) decreased from 19% (95% CI 10%, 28%) to 3% (95% CI 0%, 7%). Stool consistency improved after treatment, and the frequency of normal stool types (Bristol Stool Scale score 3-5) increased from 28% (95% CI 18%, 39%) to 76% (95% CI 66%, 86%). Participant satisfaction was high, with 86% reporting considerable benefits (Likert scores 5-7). Repeated FMT was generally well tolerated, with most AEs being mild and self-limiting. Fifteen serious AEs were documented, of which only one was deemed to be possibly related to FMT. CONCLUSIONS/INTERPRETATION: Repeated, on-demand FMT is effective and safe for long-term treatment of individuals with type 1 diabetes and severe diabetic gastroenteropathy. TRIAL REGISTRATION: ClinicalTrials.gov NCT04749030 FUNDING: The study was funded by a Steno Collaborative Grant (no. 0058906).
引用
- Høyer KL, Kornum DS, Baunwall SMD, et al. Repeated faecal microbiota transplantation for individuals with type 1 diabetes and gastroenteropathy. Diabetologia. 2025. PMID: 40965701. doi:10.1007/s00125-025-06544-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。